ECSP10010183A - Producto de dispersión sólida de drogas basadas en n-aril-urea - Google Patents

Producto de dispersión sólida de drogas basadas en n-aril-urea

Info

Publication number
ECSP10010183A
ECSP10010183A EC2010010183A ECSP10010183A ECSP10010183A EC SP10010183 A ECSP10010183 A EC SP10010183A EC 2010010183 A EC2010010183 A EC 2010010183A EC SP10010183 A ECSP10010183 A EC SP10010183A EC SP10010183 A ECSP10010183 A EC SP10010183A
Authority
EC
Ecuador
Prior art keywords
solid dispersion
urea
aril
dispersion product
based drugs
Prior art date
Application number
EC2010010183A
Other languages
English (en)
Inventor
Rudolf Schroeder
Tanja Heitermann
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of ECSP10010183A publication Critical patent/ECSP10010183A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un producto que comprende al menos un agente con actividad farmacéutica basado en N-aril urea que se obtiene mediante a) la preparación de una mezcla líquida que contiene al menos un agente activo, al menos un agente formador de matriz farmacéuticamente aceptable, al menos un agente tensioactivo farmacéuticamente aceptable y al menos un solvente, y b) la eliminación de los uno o más solventes de la mezcla líquida, para obtener el producto de dispersión sólida.
EC2010010183A 2007-10-19 2010-05-17 Producto de dispersión sólida de drogas basadas en n-aril-urea ECSP10010183A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99961807P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
ECSP10010183A true ECSP10010183A (es) 2010-06-29

Family

ID=40089463

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010183A ECSP10010183A (es) 2007-10-19 2010-05-17 Producto de dispersión sólida de drogas basadas en n-aril-urea

Country Status (18)

Country Link
EP (1) EP2197425A2 (es)
JP (1) JP2011500649A (es)
KR (1) KR20100087170A (es)
CN (1) CN101827584A (es)
AU (1) AU2008313622A1 (es)
BR (1) BRPI0818340A2 (es)
CA (1) CA2699301A1 (es)
CO (1) CO6270206A2 (es)
CR (1) CR11442A (es)
DO (1) DOP2010000117A (es)
EC (1) ECSP10010183A (es)
GT (1) GT201000102A (es)
MX (1) MX2010004291A (es)
PA (1) PA8800101A1 (es)
RU (1) RU2010119929A (es)
UA (1) UA100865C2 (es)
WO (1) WO2009050291A2 (es)
ZA (1) ZA201002095B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
BR112012031516A2 (pt) * 2010-06-09 2016-11-08 Abbott Lab dispersões sólidas contendo inibidores de quinase
RU2622015C2 (ru) 2011-11-11 2017-06-08 Новартис Аг Способ лечения пролиферативного заболевания
SI2782557T1 (sl) * 2011-11-23 2019-02-28 Array Biopharma, Inc., Farmacevtske formulacije
WO2014003677A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising solid dispersion particles containing tadalafil
WO2014003678A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil
ES3063790T3 (en) 2015-06-09 2026-04-20 Lonza Sales Ag Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1959926A1 (en) * 2005-10-25 2008-08-27 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
WO2007066189A2 (en) * 2005-12-09 2007-06-14 Pfizer Products Inc. Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
EP2089003A1 (en) * 2006-11-09 2009-08-19 Abbott GmbH & Co. KG Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Also Published As

Publication number Publication date
CN101827584A (zh) 2010-09-08
WO2009050291A3 (en) 2010-04-08
AU2008313622A1 (en) 2009-04-23
UA100865C2 (ru) 2013-02-11
CA2699301A1 (en) 2009-04-23
EP2197425A2 (en) 2010-06-23
JP2011500649A (ja) 2011-01-06
CR11442A (es) 2010-09-06
BRPI0818340A2 (pt) 2015-04-22
CO6270206A2 (es) 2011-04-20
KR20100087170A (ko) 2010-08-03
WO2009050291A2 (en) 2009-04-23
PA8800101A1 (es) 2009-05-15
RU2010119929A (ru) 2011-11-27
GT201000102A (es) 2012-03-12
DOP2010000117A (es) 2010-05-15
MX2010004291A (es) 2010-08-02
ZA201002095B (en) 2011-11-30

Similar Documents

Publication Publication Date Title
ECSP10010184A (es) Producto de dispersión sólida que contiene un compuesto a base de n-aril-urea
ECSP10010183A (es) Producto de dispersión sólida de drogas basadas en n-aril-urea
AR080736A1 (es) Composicion farmaceutica de disolucion rapida, usualmente bucodispersable, y proceso para prepararla
UY30139A1 (es) Formulacion farmaceuica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
CO6470799A2 (es) Composición farmacéutica oral auto-microemulsificante de un farmaco hidrofílico y método de preparación de ésta
CR9292A (es) Comprimidos con dispersion mejorada de la sustancia farmacologica
CL2015001961A1 (es) (divisional solicitud 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos
WO2010015567A3 (en) Controlled release formulations using intelligent polymers
WO2010041141A3 (en) Oil-based foamable carriers and formulations
MX2009009463A (es) Preparacion de una pelicula de rapida disolucion/desintegracion que tiene una alta proporcion de ingrediente activo.
AR059359A1 (es) Formulaciones farmaceuticas que contienen pleconaril
UY32761A (es) Preparaciones termoestables y preparaciones insulinicas estables a las vibraciones
AR051969A1 (es) Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y el manejo de lesiones del sistema nervioso central
CO6251200A2 (es) Metodo para modular la tasa de liberacion de ingredientes activos microencapsulados usado paa la proteccion de cultivos
CY1110037T1 (el) Σκευασματα για βενζιμιδαζολυλ πυριδυλ αιθερες
AR059357A1 (es) Formulaciones farmaceuticas
PE20081406A1 (es) Composiciones farmaceuticas de flunixina
PE20110019A1 (es) Composicion farmaceutica que contiene un sensibilizante de insulina y un secretagogo de insulina
CL2007002754A1 (es) Composicion emulsionante de agroquimicos activos, tensoactivos, solventes aromaticos, diacetato de propilenglicol, 1,3-dimetil-2-imidazolidinona y auxiliares de formulacion; solvente para compuestos agroquimicos; dilucion que comprende la composicion
AR093402A1 (es) Producto de comicronizacion que comprende acetato de ulipristal
CL2007001981A1 (es) Composicion que comprende al menos un principio activo agroquimico del grupo de los piretroides, al menos un tensioactivo, y al menos un disolvente no miscible en agua; procedimiento para la lucha contra las plagas animales; y su uso.
AR052787A1 (es) Proceso para preparar formulaciones de sustancias activas lipofilicas mediante liofilizacion por atomizacion
CL2011001207A1 (es) Extruidos que contienen al menos una sustancia farmacéuticamente activa en forma de agujas, tal que la relación entre el tamaño de partículas de la sustancia farmacéuticamente activa con forma de agujas y el diámetro de la cadena es de al menos 1:20; composición farmacéutica; y su uso para preparar medicamentos.
AR062626A1 (es) Comprimidos de polimero de poliestireno sulfonato, su preparacion y uso
CO6270249A2 (es) Fibra, pelicula o espuma que comprende un plastificador y un gel ligado a arcilla cargado y metodos para su produccion